We evaluated the efficacy (objective response rate [ORR], disease control rate [DCR], PFS, OS) and safety profile of double-dose icotinib (250 mg TID) in a cohort of patients with EGFR 19del or L858R mutant lung adenocarcinoma, focusing particularly on outcomes in clinically relevant subgroups and exploring the prognostic value of systemic inflammation biomarkers. The gene discussed is EGFR; the disease is lung adenocarcinoma.